Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Trinh, Ba K. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S510000, C549S511000
Reexamination Certificate
active
09265307
ABSTRACT:
The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.
REFERENCES:
patent: 4088646 (1978-05-01), Ishida et al.
patent: 4550109 (1985-10-01), Folkers et al.
patent: 4636494 (1987-01-01), Growden et al.
patent: 4692441 (1987-09-01), Alexander et al.
patent: 4729989 (1988-03-01), Alexander
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4814470 (1989-03-01), Colin et al.
patent: 4857653 (1989-08-01), Colin et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4933324 (1990-06-01), Shashoua
patent: 4939174 (1990-07-01), Shashoua
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5112863 (1992-05-01), Hashimoto et al.
patent: 5116624 (1992-05-01), Horrobin et al.
patent: 5120760 (1992-06-01), Horrobin
patent: 5141958 (1992-08-01), Crozier-Willi et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5214062 (1993-05-01), Mark et al.
patent: 5216023 (1993-06-01), Literati-Nagy et al.
patent: 5216142 (1993-06-01), Horribin et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5246726 (1993-09-01), Horrobin et al.
patent: 5250722 (1993-10-01), Bombardelli et al.
patent: 5276020 (1994-01-01), Horrobin et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5284876 (1994-02-01), Shashoua et al.
patent: 5308832 (1994-05-01), Garleb et al.
patent: 5336684 (1994-08-01), Murray et al.
patent: 5356928 (1994-10-01), Murray et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5453520 (1995-09-01), Bombardelli et al.
patent: 5453521 (1995-09-01), Gaullier et al.
patent: 5466841 (1995-11-01), Horrobin et al.
patent: 5468754 (1995-11-01), Hausheer et al.
patent: 5473055 (1995-12-01), Mongelli et al.
patent: 5476954 (1995-12-01), Bourzat et al.
patent: 5484809 (1996-01-01), Hostetler et al.
patent: 5504102 (1996-04-01), Agharkar et al.
patent: 5516800 (1996-05-01), Horrobin
patent: 5534499 (1996-07-01), Ansell
patent: 5545719 (1996-08-01), Shashoua
patent: 5580556 (1996-12-01), Horrobin
patent: 5580899 (1996-12-01), Mayhew et al.
patent: 5597719 (1997-01-01), Freed et al.
patent: 5604216 (1997-02-01), Horrobin
patent: 5654290 (1997-08-01), Bayon et al.
patent: 5750572 (1998-05-01), Bruzzese
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 5925669 (1999-07-01), Katz et al.
patent: 5955459 (1999-09-01), Bradley et al.
patent: 5977174 (1999-11-01), Bradley et al.
patent: 5985854 (1999-11-01), Kozak
patent: 5994392 (1999-11-01), Shashoua
patent: 6077837 (2000-06-01), Kozak
patent: 6080877 (2000-06-01), Swindell et al.
patent: 6136796 (2000-10-01), Kozak
patent: 6166089 (2000-12-01), Kozak
patent: 6245811 (2001-06-01), Horrobin et al.
patent: 6281376 (2001-08-01), Whittaker et al.
patent: 6291690 (2001-09-01), Mayhew et al.
patent: 2001/0006962 (2001-07-01), Myhren et al.
patent: 2602175 (1976-07-01), None
patent: 422 4737 (1994-02-01), None
patent: 0 030 009 (1981-06-01), None
patent: 0 599 576 (1994-01-01), None
patent: 0 615 752 (1994-09-01), None
patent: 0 693 498 (1996-01-01), None
patent: 2 698 269 (1997-08-01), None
patent: 75-9469 (1975-01-01), None
patent: 75-427/1983 (1983-04-01), None
patent: 59025327 (1984-02-01), None
patent: 59-204175 (1984-11-01), None
patent: 61204136 (1984-11-01), None
patent: 1153629 (1989-06-01), None
patent: 1203331 (1989-08-01), None
patent: 1287022 (1989-11-01), None
patent: 6016548 (1994-01-01), None
patent: 6072868 (1994-03-01), None
patent: 8027010 (1996-01-01), None
patent: 7082146 (1996-03-01), None
patent: 815133 (1996-06-01), None
patent: 8163991 (1996-06-01), None
patent: 9025231 (1997-01-01), None
patent: 9030963 (1997-02-01), None
patent: WO 85/00520 (1985-02-01), None
patent: WO 89/07938 (1989-09-01), None
patent: WO 92/20362 (1992-11-01), None
patent: WO 93/11668 (1993-06-01), None
patent: WO 94/07880 (1994-04-01), None
patent: WO 94/11547 (1994-05-01), None
patent: WO 94/12530 (1994-06-01), None
patent: WO 94/13654 (1994-06-01), None
patent: WO 94/22887 (1994-10-01), None
patent: WO 94/24107 (1994-10-01), None
patent: WO 95/01969 (1995-01-01), None
patent: WO 95/13270 (1995-05-01), None
patent: WO 95/13271 (1995-05-01), None
patent: WO 95/33736 (1995-12-01), None
patent: WO 96/01259 (1996-01-01), None
patent: WO 96/04001 (1996-02-01), None
patent: WO 96/12696 (1996-05-01), None
patent: WO 96/27380 (1996-09-01), None
patent: WO 96/34855 (1996-11-01), None
patent: WO 96/34858 (1996-11-01), None
patent: WO 97/44026 (1997-11-01), None
patent: WO 97/44063 (1997-11-01), None
patent: WO 97/44336 (1997-11-01), None
patent: WO 98/17325 (1998-04-01), None
patent: WO 98/32718 (1998-07-01), None
patent: WO 99/52887 (1999-10-01), None
patent: 9603433 (1996-10-01), None
International Search Report, PCT/US 00/06160, International Filing Date: Sep. 3, 2000.
Ansari et al., “Fatty acid conjugates of xenobiotics,”Toxicol. Lett.(1995), 75, 1-17.
Chen, et al. “Taxol Structure-Activity Relationships: Synthesis and Biological Evaluation of Taxol Analogs Modified at C-7,”Bioorganic&Medicinal Chemistry Letters,vol. 4, No. 18, pp. 2223-2228, 1994.
de Groot et al., “Synthesis and Biological Evaluation of 2′-Carbamate-Linked and 2′-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin,”J. Med. Chem.,2000, vol. 43, pp. 3093-3102.
Dischino et al., “Synthesis of the Monosodium Salt of Carbon-14 Labeled Paclitaxel (Taxol®) 2′-Ethyl Carbonate 7-Phosphonooxymethyl Ether, a Potential Prodrug of Paclitaxel”,J. of Labelled Compounds and Radiopharmaceuticals,vol. XXXIX, No. 2, 1997.
Greenwald et al., “Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates”,J. Org. Chem.1995, 60, pp. 331-336.
Halmos et al., “Fatty acid conjugates of 2′-deoxy-5-fluorouridine as prodrugs for the selective delivery of 5-fluorouracil to tumor cells,”Biochem. Pharmacol.(1992), 44(1), 149-155.
Hong et al., “Nucleoside-ether lipid conjugates as biotransformed prodrugs of antitumor and antiviral nucleosides,”J. Lipid Mediators Cell Signalling(1994), 19, 159-161.
Pouillart “Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies,”Life Sci.(1998), 63(20), 1739-1760.
UEDA, et al. “Synthesis and Antitumor Evaluation of 2′-Oxycarbonylpaclitaxels (Paclitaxel-2′-Carbonates)”,Bioorganic&Medicinal Chemistry Letters,vol. 4, No. 15, pp. 1861-1864, 1994.
Anel, A., et al., “Increased Cytotoxicity Of Polyunsaturated Fatty Acids On Human Tumoral B And And T-Cell Lines Compared With Normal Lymphocytes”,Leukemia,(1992), 6(7):680-688.
Anel, B., et al. “Cytotoxicity Of Chlorambucil And Chlorambucil-Fatty Acid Conjugates Against Human Lymphomas And Normal Human Peripheral Blood Lymphocytes”,Biochem Pharmacol,(1990),40(6):1193-1200.
Begin, M.E., et al., “Differential Killing Of Human Carcinoma Cells Supplemented With N-3 And N-6 Polyunsaturated Fatty Acids”,J Natl Cancer Inst,(1986), 77(5):1053-1062. (Abstract).
Bourat, et al., “Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drug”,Med. Chem. Proc. Int. Symp.5th (1976) pp. 105-114.
Burns, C.P., et al., “Effect Of Docosahexaenoic Acid On Rate Of Differentiation Of H1-60 Human Leukemia”,Cancer Res,(1989), 49:3252-3258.
Carboni et al., “Synthesis of a Photoaffinity Analog of Taxol as an Approach to Identify the Taxol Binding Site on Microtubules”,Journal of Medicinal Chem.(Sep. 8, 1992).
Chajes, V., et al., “Influence Of N-3 Fatty Acids On The Growth Of Human Breast Cancer Cel
Anthony Forrest
Bradley Matthews O.
Fisher Mark
Webb Nigel L.
Luitpold Pharmaceuticals, Inc.
Trinh Ba K.
Wolf Greenfield & Sacks P.C.
LandOfFree
Fatty acid-anticancer conjugates and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fatty acid-anticancer conjugates and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fatty acid-anticancer conjugates and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865319